多瑞医药(301075.SZ)发布前三季度业绩，归母净亏损7972.77万元

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and an increase in net losses for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 137 million yuan, representing a year-on-year decrease of 43.07% [1] - The net loss attributable to shareholders of the listed company was 79.7277 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 84.9485 million yuan [1] - The basic loss per share was 1.0064 yuan [1]